Thermo Fisher Scientific beta Amyloid (N-terminal) Polyclonal Antibody

Applications

Immunohistochemistry (IHC)

• Tested Dilution: Assay-dependent

Functional Assay

• Tested Dilution: Assay-dependent

Product Specifications

Target Information

Amyloid beta peptide (Abeta/Beta-amyloid) is the major constituent of amyloid plaques in the brains of individuals afflicted with Alzheimer’s disease. Abeta peptide is 40–43 amino acids long and generated from the beta-amyloid precursor protein (beta APP) in a two-step process.
The first step involves cleavage of the extracellular, amino-terminal domain of beta APP by the aspartyl protease beta-secretase (BACE), which is synthesized as a propeptide and activated by the prohormone convertase, furin.
Beta APP cleavage by mature BACE results in secretion of a segment of beta APP and a membrane-bound remnant, which is further processed by gamma-secretase. Gamma-secretase cleaves an intra-membrane site in the carboxyl-terminal domain of beta APP, generating the amyloid beta peptide.
Gamma-secretase is a multi-subunit complex containing presenilin-1 and -2 as central components. The transmembrane glycoprotein nicastrin associates with presenilins and binds to the carboxyl-terminus of beta APP, modulating amyloid beta peptide production.

Abeta is an extracellular filamentous protein component of amyloid cores and neuritic plaques, also found in neurofibrillary tangles. Alzheimer’s disease, the most common cause of senile dementia, is characterized by abnormal filamentous protein deposits in the brain. Beta amyloid deposits are also detected in Lewy body dementia, Down’s syndrome, amyloidosis (Dutch type), cerebroarterial amyloidosis (cerebral amyloid angiopathy), and the Guam Parkinson-Dementia complex.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.